イノベーションハブ
/
ウェビナー
/
FDA Patient-Focused Drug Development (PFDD) Guidance

FDA Patient-Focused Drug Development (PFDD) Guidance

Date:

February 1, 2023

Time (ET):

9:38 AM

今すぐ登録

This is part one of a two part ISPOR webinar series. The FDA is developing Patient-Focused Drug Development (PFDD) guidance to inform the inclusion of patient experience when developing new medical therapies and products. This is a four-part guidance series, with two final guidances released, a third draft guidance released and a fourth guidance under development. The PFDD guidance is anticipated to be influential in the field of health economics and outcomes research. In this webinar series, we will hear from patients and FDA staff to learn what is covered in this guidance series and what these new guidances mean for patient-focused drug development.

Open to all ISPOR Members and Non-members. Learn more.

トピック

Health Economics & Outcomes Research (HEOR)

FDA Patient-Focused Drug Development (PFDD) Guidance

Open to all ISPOR Members and Non-members. Learn more.

トピック

今すぐ視聴する

関連コンテンツ

Getting COA strategy right from the start: Early endpoint decisions that strengthen evidence and reduce risk

Filling the Gap: Integrating Patient-Generated Data into Real-World Evidence

Getting COA strategy right from the start: Early endpoint decisions that strengthen evidence and reduce risk

Filling the Gap: Integrating Patient-Generated Data into Real-World Evidence

Closing Gaps in Care: Health Equity and the Inflation Reduction Act - A Cutting Edge Conversation

Network meta-analysis and its role in evidence-based decision-making

Addressing Orphan and Rare Diseases - A Cutting Edge Conversation

Joint Clinical Assessment 2025: Pioneering Pathways for Oncology, Advanced Therapies & Rare Diseases

RWE reality check: Routine patient health records and regulatory requirements

"S" Stands for Systematic: Demystifying the Systematic Literature Review

Survival Analysis for Immature Data: A Review of Techniques and Lessons Learned

Market Access - Transforming BioTech Commercial Decisions?

The Scientific and Operational Elegance of Study Replication with Real-World EHR Data: A Vitiligo and Alopecia Example

Insights from the 2024 Salary Survey Report by HealthEconomics.com

Integrated Evidence Generation Planning: Driving Successful Reimbursement and Life Cycle Management

Patient Voices Matter: Transforming Industry-Sponsored Real-World Evidence with Patient-Centric Approaches

Strategies to Optimize Commercialization of Oncology Treatments for Younger Adults

Navigating the Clinical Outcomes Maze: An Overview of Clinical Outcomes Assessments and Why Training Matters

Cutting Edge Conversations: Value, Access and Evidence - Biotech Market Access

EU HTA Joint Clinical Assessments: Navigating Potential Challenges Ahead of 2025

Bridging the Gap: Strategies for Patient-Centered Real-World Evidence in Rare Diseases

Pharma can target ultra-rare conditions ‚Äî the next step is financing them

Advancing identity data management for digital engagement: How leading organizations are doing it

Keeping up with demands for healthcare outside of the hospital: Critical ways tech supports the distributed care model

Driving value from healthcare data: How integrated cloud-based data is foundational to drive enterprise change

Closing the gaps of getting data to make decisions

How Digital Health Can Empower Cancer Patients

Clinical Trial Innovation: How Healthcare Technology is Evolving

Connected communities: Advancing population health through data and emerging technology

Certified Corporate Wellness Specialist(CCWS): Is It For Me?

The reimagined hospital: How health systems are keeping up with new tech

L7|LIVE SF - Tuesday, June 13th, 2023

Transforming Healthcare Using Big Data and Remote Monitoring

Synthesise RWE and AI. Transform patient-driven healthcare

Endpoints at #DIA23

From Challenges to Opportunities: Navigating the EU MDR as a Medical Device Manufacturer

Ushering in the new era of payvider integration

Partnering with NHS in a crisis: The role for industry

Unlock the Power of Data Review & Collaboration: Maximizing Trial Success

HTA Implementation in the MEA Region - an Overview from WHO and Country Updates

Improving Treatment Access & Outcomes by Integrating Social Determinants of Health Data with Real-World Evidence

How to Supercharge Real World Evidence Generation in Phase IV Trials

Webcast: Taking the Complexity Out of Leveraging Health Plan Price Transparency Data

FDA Patient-Focused Drug Development (PFDD) Guidance

Creating Digital Biomarkers with Real-World and Existing Data by Xtalks

Beyond the payment variance report: How to resolve common, costly underpayment issues

Webcast: Strategies to Simplify Insurance Discovery

Looking Beyond Survival Data: Understanding the Value of Non-OS Endpoints in Oncology Reimbursement Decision-Making

Measuring the intangible- what is the true value of a "patient centric" initiative

Champion a seamless end-to-end insight generation process

Different HTA Perspectives on Reliably Estimating Treatment Effects

The Biotech landscape: Market trends, priorities, predictions, and pathways to FDA approval

Fit for Local Context? Establishing or Improving Deliberative Processes for HTA

Evidence Matters 2022

US Drug Pricing Reform: Potential impact on Pharma HEOR Evidence Generation - September 8th

When the Barrier to a Breakthrough Drug is You Can't Make It - September 28th

Cell & Gene Day 2022 | Virtual Event | August 24th

Biology's modern LIMS for labs of the future - August 17 | 12:00 pm - 1:00 pm EDT

Confronting care inequities in hospital medicine - August 18th, 2022

Pain R&D: Plenty of pain to go around, but who's making gains?

AI and Machine Learning Technologies: The New Normal of the Pharmaceutical Industry - July 27th

Digital Transformation to Support Operational, Therapeutic and Clinical Decision Making

Selecting Rapid Review Methods for Health Technology Assessment

Predicting Payer Uptake with Precision

It's Not FAIR! Improving Data Publishing Practices in Research-Interoperability

Exploring Best Practices and Innovation in New Registry Handbook: Part 2 - Understanding Quality

Rise of the Robots 2.0: Real Talk About Artificial Intelligence In Systematic Reviews

Informational Webinar & Alumni Panel: Online MS Degree, Pharm Outcomes & Policy

Patient-Centric RWE Research & Remote Monitored Care: Learnings from a support program leveraging telehealth & connected devices

Partnering with Disease Registries: The Value and Impact for Real-World Evidence Generation

Minimizing the Impact of Cross-Cultural Differences in COA Translations

What Every Researcher Needs to Know About Using Medicare Data for Real World Evidence

Medicare Part D: Price Negotiation Panel Discussion

Finding Value in Linking Real-World Data with Social Determinants of Health

Health Economic and Outcome Research (HEOR) for Medical Technologies for the US Healthcare Systems